AD01 Follow up Extension Visit

Affiris AG17 enrolled

Overview

Patients who were vaccinated with AFFITOPE AD01 during AFFiRiS001 will undergo a long-term follow-up period to get more information regarding the safety profile of AFFITOPE AD01.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Alzheimer´s Disease

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Written informed consent signed and dated by the patient or the patient's legal representative and the caregiver. * Patients having participated in AFFiRiS 001 and AFF003 and having received ≥1 vaccination with AFFITOPE AD01 * Availability of a partner/caregiver knowing the patient Exclusion Criteria: * Patients having received no vaccination with AFFITOPE AD01 * History of questionable compliance to visit schedule

Locations (1)

Univ. Klinik für Neurologie

Vienna, Austria

Outcomes

Primary Outcomes

Long term tolerability and safety of AFFITOPE AD01

retrospective assessment of safety data

Time frame: One year.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.